Tern Plc CEO Albert Sisto increases interest in company

Tern plc

Tern Plc (LON:TERN), the company focused on value creation from Internet of Things (“IoT”) technology businesses, announced today that on the 23rd August 2022, the Company entered into a direct subscription with Albert Sisto, Chief Executive Officer, via the Albert E Sisto Revocable Trust, for a total of 200,000 new Ordinary Shares of 0.02p pence each at an issue price of 9.9p pence per share.

The Subscription has been undertaken by the Company to allow Mr. Sisto to increase his interest in the Company, which is otherwise difficult for Mr. Sisto to do, due to his primary residency and tax status in the United States of America. The Issue Price is equal to the closing mid-market price of the Company’s Ordinary Shares on AIM on the business day prior to this announcement.

Albert Sisto’s total beneficial interest following this transaction will be 10,616,666 Ordinary Shares, representing approximately 3.01% of the voting rights in the Company’s enlarged share capital following the issue of the Subscription Shares. The FCA notification, made in accordance with the requirements of the UK Market Abuse Regulation, is appended below.

Application has been made for the 200,000 Subscription Shares to be admitted to trading on AIM, which is expected to take place on or around 30th August 2022. Once issued, the Subscription Shares will rank pari passu in all respects with the existing Ordinary Shares of the Company.

Total Voting Rights

Following Admission, the Tern plc issued ordinary share capital will consist of 352,214,701 Ordinary Shares, all of which carry one voting right per share. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of Ordinary Shares and voting rights in the Company will be 352,214,701. With effect from Admission, this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA’s Disclosure Guidance and Transparency Rules.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Talking Medicines is building the AI layer beneath pharma marketing

Talking Medicines is shifting pharma marketing from content creation to data control, building the layer AI tools rely on to deliver credible, measurable clinical messaging.

A shift in how IoT is secured by default

KeyScaler 2025 transforms IoT security by automating trust across every device’s lifecycle, from onboarding to decommissioning, turning scalable connectivity and compliance into a built-in feature.

Turning employee sentiment into hard operational data

Workforce wellbeing is becoming a source of operational data, and the companies acting early are already reducing risk.

Tern Plc Extends Convertible Loan Maturities in Talking Medicines to Strengthen Exit Strategy

Tern Plc extends all convertible loan maturities in Talking Medicines to 2029, enhancing its strategic position for future exit.

A new frontier for medical device trust and patient safety

Connected medical device risk is rising and a platform that automates identity, credential and data‑protection lifecycles may become an infrastructure segment worth watching.

When HCP Dialogue Becomes Quantifiable Intelligence

Talking Medicines’ DrugVoice platform turns real‑world HCP dialogue into measurable insight, letting brand‑teams forecast message resonance before launch.

Search

Search